Nuria Pardo
Barcelona, CT, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications
MORPHEUS-Lung: biomarkers and clinical response to atezolizumab + bevacizumab + stereotactic body radiotherapy in patients with metastatic non-small cell lung cancer.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: December 10, 2025
Somatic copy number alterations profiling in non-small cell lung cancer and their correlation with clinical efficacy in first-line treatment.
Journal: Genome medicine
Published: November 07, 2025
Immune Checkpoint Inhibitors and Interstitial Lung Disease: A Comprehensive Review of Pathogenesis, Diagnosis, and Management.
Journal: Open respiratory archives
Published: October 10, 2025
Atezolizumab and bevacizumab, with or without radiotherapy, versus docetaxel in patients with metastatic non-small cell lung cancer previously treated with a checkpoint inhibitor and chemotherapy: results from the randomized, phase Ib/II MORPHEUS-Lung study.
Journal: Journal for immunotherapy of cancer
Published: June 16, 2025
Dynamic changes in circulating tumor DNA assessed by shallow whole-genome sequencing associate with clinical efficacy of checkpoint inhibitors in NSCLC.
Journal: Molecular oncology
Published: December 16, 2022
High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC.
Journal: Journal for immunotherapy of cancer
Published: February 24, 2022
Overview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying Cancer.
Journal: Frontiers in medicine
Published: February 14, 2022
Hepatic Rupture as the Initial Presentation of an EGFR-Mutated Lung Adenocarcinoma: A Case Report.
Journal: Frontiers in oncology
Published: December 16, 2021
Last Updated: 09/26/2026